Progenika Biopharma

Industry / private company


Location: Derio, Spain (ES) ES

ISNI: -

close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Reverse switching from the biosimilar SB2 to the originator infliximab in previously switched patients with inflammatory bowel diseases: results of a prospective long-term cohort study (2024) Fischer S, Donhauser M, Cohnen SE, Fietkau K, Vetter M, Grübel-Liehr M, Dietrich P, et al. Journal article Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab (2021) Fischer S, Cohnen S, Klenske E, Schmitt H, Vitali F, Hirschmann S, Ramming A, et al. Journal article Efficacy, safety, and pharmacokinetics after switching from infliximab originator to biosimilar SB2 in inflammatory bowel disease patients: A long-term observational, prospective cohort study (2020) Fischer S, Mesfin SE, Klenske E, Schmitt H, Vitali F, Hirschmann S, Ramming A, et al. Conference contribution Point of Care detection of anti-infliximab antibodies in inflammatory bowel disease patients treated with the biosimilar SB2: performance comparison with ELISA (2019) Atreya R, Schmitt H, Fischer SM, Neurath M, Rekalde X, Nagore D, Ametzazurra A Conference contribution Drug Levels in the Maternal Serum, Cord Blood and Breast Milk of a Ustekinumab-Treated Patient with Crohn's Disease (2019) Klenske E, Osaba L, Nagore D, Rath T, Neurath M, Atreya R Journal article Clinical outcomes and immunogenicity analysis over 6 months following a switch from originator infliximab (Remicade (R)) to the biosimilar SB2 (Flixabi (R)) in inflammatory bowel disease patients (2018) Fischer SM, Klenske E, Schmitt H, Vitali F, Hirschmann S, Koch F, Ramming A, et al. Conference contribution